H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT manufacturers
- ARG-PRO-PRO-GLY-PHE
-
- $7.00
-
2020-02-17
- CAS:23815-89-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| | H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Basic information |
| | H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO | | pka | 3.50±0.10(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Arg-Pro-Pro-Gly-Phe | | InChIKey | USSUMSBPLJWFSZ-UHFFFAOYSA-N | | SMILES | NC(CCCNC(N)=N)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(Cc3ccccc3)C(O)=O |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Usage And Synthesis |
| Uses | Biologically active fragment of bradykinin | | Biochem/physiol Actions | The bradykinin (BK) fragment (1-5) (RPPGF) is among the most stable of naturally occurring metabolites. It may be used as a marker for BK production in vivo. It is known that an intact Arg residue in the C-terminus is required for biological activities. BK 1-5 is the minimal peptide that inhibited α-thrombin-induced platelet aggregation and secretion and calcium mobilization. It also prevented α-thrombin from cleaving the thrombin receptor peptide, NATLDPRSFLLR, between arginine and serine. Such antithrombin activities of BK 1-5 may contribute to the cardioprotective nature of kinins. | | in vivo | Bradykinin is a short-lived vasoactive peptide, with a reported half-life in vivo of 17 s, that is rapidly metabolized in the circulation to Bradykinin (1-5). Bradykinin (1-5), the product of two sequential cleavages of Bradykinin by ACE at the Pro7-Phe8 and Phe5-Ser6bonds, has been identified as the major stable metabolite of Bradykinin in vivo in human subjects, with a terminal half-life of minutes. Both Bradykinin and Bradykinin (1-5) inhibit α- and γ-thrombin-induced platelet aggregation (P<0.01 versus baseline). Bradykinin (1-5) inhibits γ-thrombin-induced platelet aggregation 50% at a calculated dose of 183±3 pmol/min. Neither Bradykinin nor Bradykinin (1-5) affects thrombin receptor-activating peptide-induced platelet aggregation, consistent with the hypothesis that Bradykinin and Bradykinin 1-5 inhibit thrombin-induced platelet aggregation by preventing cleavage of the thrombin receptor and liberation of thrombin receptor-activating peptide. Bradykinin (1-5) significantly attenuates α-thrombin-induced platelet aggregation but not TRAP 1-6-induced platelet aggregation. Bradykinin (1-5) potently inhibits γ-thrombin (500 nM)-induced platelet aggregation with an ED50 of 183±2 pmol/min[1]. |
| | H-ARG-PRO-PRO-GLY-PHE-OH TRIFLUOROACETATE SALT Preparation Products And Raw materials |
|